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ABSTRACT: Factor Va, the cofactor of prothrombinase, is composed of heavy and light chains associated
noncovalently in the presence of divalent metal ions. The COOH-terminal region of the heavy chain contains
acidic amino acid clusters that are important for cofactor activity. In this work, we have investigated the role
of amino acid region 659-663, which contains five consecutive acidic amino acid residues, by site-directed
mutagenesis. We have generated factor V molecules in which all residues were mutated to either lysine (factor
V
5K) or alanine (factor V
5A). We have also constructed a mutant molecule with this region deleted (factor
V
Δ659-663). Therecombinant moleculesalong with wild-typefactorV(factorV
WT)were transiently expressed
in mammalian cells, purified, and assessed for cofactor activity. Two-stage clotting assays revealed that the
mutant molecules had reduced clotting activities compared to that of factor Va
WT. Kinetic analyses of
prothrombinase assembled with the mutant molecules demonstrated diminished kcat values, while the affinity
of all mutant molecules for factor Xa was similar to that for factor Va
WT. Gel electrophoresis analyses of
plasma-derived and recombinant mutant prothrombin activation demonstrated delayed cleavage of pro-
thrombin at both Arg
320 and Arg
271 by prothrombinase assembled with the mutant molecules, resulting in
meizothrombin lingering throughout the activation process. These results were confirmed after analysis of
thecleavageofFPR-meizothrombin.Ourfindingsprovidenewinsightsintothestructuralcontributionofthe
acidic COOH-terminal region of factor Va heavy chain to factor Xa activity within prothrombinase and
demonstrate that amino acid region 659-663 from the heavy chain of the cofactor contributes to the
regulation of the rate of cleavage of prothrombin by prothrombinase.
The proteolytic conversion of prothrombin to thrombin is
catalyzed by the prothrombinase complex composed of the
enzyme, factor Xa, and the cofactor, factor Va, assembled on a
membranesurfaceinthepresenceofCa
2þ (1,2).FactorXaalone
can activate prothrombin following sequential cleavages at
Arg
271 and Arg
320, yielding the transient inactive intermediate
prethrombin-2.However,theinteractionoffactorVawithfactor
Xa on a membrane or cell surface in the presence of divalent
metal ions and formation of the prothrombinase complex results
inthereversalofthe orderofcleavage anda300000-foldincrease
in the catalytic efficiency of factor Xa for thrombin generation.
A first cleavage of prothrombin by prothrombinase at Arg
320
produces the active intermediate meizothrombin, while the second
cleavage at Arg
271 produces thrombin (3-6). Thrombin and
prothrombin contain two positively charged binding regions
[anion binding exosite I (ABE-I) and anion binding exosite II
(ABE II)] that are crucial for protein function. Initial cleavage of
prothrombin at Arg
320 by prothrombinase, which is absolutely
factor Va-dependent, entirely exposes (pro)exosite I (7) and is
responsible for the partial formation of thrombin’s active site.
Complete formation of the active site of thrombin requires
cleavage ofmeizothrombinat Arg
271 (8, 9).Factor Vaisrequired
forthespecificrecognitionofprothrombinaseby(pro)exositeIof
prothrombin (10, 11). Proteolytic elimination of fragment 1 of
prothrombin eliminates the accelerating effect of the membrane
surface for initial cleavage at Arg
320 by prothrombinase (12, 13).
Coagulation factor V circulates in plasma at a concentration
of 20 nM, as a single-chain inactive precursor (Mr = 330000)
consisting of three subdomains in A1-A2-B-A3-C1-C2 order
(Figure 1). The molecule is activated by thrombin following
sequential cleavages at Arg
709,A r g
1018, and Arg
1545 to generate
the active cofactor (factor Va) composed of a heavy chain[Mr =
105000(A1-A2domains)]andalightchain[Mr=74000(A3-C1-
C2 domains)]. The two chains are associated via noncovalent
bonds in the presence of divalent metal ions (14). The light chain
containsthedomainsthatinteractwiththecellmembranesurface
at the place of vascular injury, while the heavy chain possesses
specific amino acid motifs that are involved in the formation and
function ofthe prothrombinase complex. We have demonstrated
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that a binding site for factor Xa is contained within the heavy
chain of the cofactor (15, 16), and we have recently shown that
tworesiduesfromthe centralportion oftheheavychainoffactor
Va (amino acid residues 334 and 335) are crucial for cofactor
function (17).
The COOH-terminal region of factor Va heavy chain is
involved in the interaction with prothrombin (18, 19). We have
recently demonstrated that a factor Va molecule lacking the last
30aminoacidsfromthecarboxyl-terminalendoftheheavychain
(amino acid residues 680-709) displayed a reduction in clotting
activity and a delay in prothrombin consumption, leading to the
accumulation of the intermediate meizothrombin during pro-
thrombin activation. Prothrombinase assembled with the same
mutant also demonstrated an increased kcat for prothrombin
a c t i v a t i o nw h e nc o m p a r e dt ot h a to fp r o t h r o m b i n a s ea s s e m b l e d
with wild-type factor Va (20). We have established that this acidic
regionisessentialforoptimalexpressionofcofactoractivitybecause
it promotes a productive interaction with prothrombin regulating
the rate of cleavage at Arg
271 by prothrombinase (20-23). This
region of the cofactor is highly acidic in nature and contains several
tyrosine residues that have been shown to be involved in factor V
activation by R-thrombin and proper cofactor function (24). This
partofthemoleculeand,moreprecisely,theDYDYQmotif(amino
acidresidues695-699) arehighlyconservedin20differentmammal
species (Figure 2). The heavy chain of the cofactor containsanother
cluster of acidic amino acids (DDDED, amino acid region 659-
663) that may also be involved in the regulation of prothrombinase
activity. This region is also conserved among species, a likely
indicator of its physiological significance (Figure 2). This study
was undertaken to evaluate the importance of amino acid region
659-663 of the factor Va heavy chain for the assembly and func-
tion of the prothrombinase complex. Our results show that this
region exerts a profound and unexpected effect on prothrombin
activation by prothrombinase.
FIGURE 1: Factor V structure and mutant molecules. The procofactor, factor V, is composed of three A domains (red), a connecting B region
(yellow),andtwoCdomains(blue).FactorVaisgeneratedfollowingthreesequentialcleavagesoffactorVbyR-thrombinatArg
709,Arg
1018,and
Arg
1545. The mutations within the acidic, hirudin-like COOH-terminal region of the heavy chain (amino acid residues 659-663) are indicated
togetherwiththe designation ofthe recombinant mutantfactor V molecules created and usedthroughoutthiswork. The acidicregion680-709,
recently shown to be involved in factor Va cofactor function, is also illustrated (20).
FIGURE 2: Comparison of the acidic COOH-terminal amino acid sequences 659-663 and 695-698 from factor Va heavy chain among species
(numbering from the human molecule, top sequence). Sequences were derived from various database sources, such as GenBank and the NCBI
TraceArchive.Theacidicaminoacidsequencesofinterestareshowninbold,togetherwithaminoacids679and680ofthecofactorthatrepresent
a specific inactivating activated protein C cleavage site. The following species are included (from top to bottom): Homo sapiens,h u m a n ;
Pan troglodytes, chimpanzee; Pongo pygmaeus, orangutan; Nomascus leucogenys, white-cheeked gibbon; Macaca mulatta,r h e s u sm o n k e y ;
Papio hamadryas, hamadryas baboon; Callithrix jacchus, white-tufted-ear marmoset; Otolemur garnettii, small-eared galago; Bos taurus,c a t t l e ;
Susscrofa,pig;Canislupusfamiliariz,dog;Myotislucifugus,littlebrownbat;Equuscaballus,horse;Dasypusnovemcinctus,nine-bandedarmadillo;
Loxodonta africana, African elephant; Dipodomys ordii, Ord’s kangaroo rat; Oryctolagus cuniculus,r a b b i t ;Cavia porcellus, domestic guinea pig;
Mus musculus, western European house mouse; Rattus norvegicus,N o r w a yr a t .8522 Biochemistry, Vol. 49, No. 39, 2010 Hirbawi et al.
EXPERIMENTAL PROCEDURES
Materials and Reagents. Diisopropyl fluorophosphate
(DFP), O-phenylenediamine (OPD) dihydrochloride, and
Coomassie Blue R-250 were purchased from Sigma (St. Louis,
MO). Factor V-deficient plasma was from Research Protein Inc.
(Essex Junction, VT). Secondary anti-mouse and anti-sheep IgG
coupled toperoxidasewas purchased fromSouthernBiotechnol-
ogy Associates Inc. (Birmingham, AL). L-R-Phosphatidylserine
(PS)
1 and L-R-phosphatidylcholine (PC) were obtained from
Avanti Polar Lipids (Alabaster, AL). Chemiluminescent reagent
ECL
þ and Heparin-Sepharose were obtained from Amersham-
Pharmacia Biotech Inc. (Piscataway, NJ). Normal reference
plasma and the chromogenic substrate H-D-hexahydrotyrosyl-
alanyl-arginyl-p-nitroanilide diacetate (Spectrozyme-TH) were
purchased from American Diagnostica Inc. (Greenwich, CT).
RecombiPlasTin used in the clotting assays was purchased from
Instrumentation Laboratory Co. (Lexington, MA). The rever-
siblefluorescentR-thrombininhibitordansylarginine-N-(3-ethyl-
1,5-pentanediyl) amide (DAPA), human R-thrombin, human
prothrombin, and active site-blocked human meizothrombin
[obtained following digestion of prothrombin with the purified
component from the venom of the snake Echis carinatus as
described previously (25), FPR-meizothrombin] were purchased
from Haematologic Technologies Inc. (Essex Junction, VT).
Human factor Xa was purchased from Enzyme Research Labo-
ratories (South Bend, IN). Human factor V cDNA was
obtained from American Type Tissue Collection (ATCC#
40515 pMT2-V, Manassas, VA). All restriction enzymes were
obtained from New England Biolabs (Beverly, MA). All molec-
ular biology and tissue culture reagents, specific primers, and
medium were purchased from Gibco, Invitrogen Corp. (Grand
Island, NY) or as indicated. Recombinant wild-type pro-
thrombin, prothrombin rMZ-II that has only one cleavage site
for factor Xa(i.e.,Arg
320), andprothrombin rP2-II that has only
one cleavage site for factor Xa (i.e., Arg
271) were prepared and
purified as previously described (26) and provided by M. Nesheim
(Queen’s University, Kingston, ON). Alternatively, cells stably
transfected with the rMZ-II cDNA provided by M. Nesheim
were grown and the media collected as described previously (26).
rMZ-II was purified to homogeneity by fast liquid chromatog-
raphy (FPLC) as initially described (26). Human factor V
monoclonal antibodies (RHFVHC17 and RHFVLC9) used for
immunoblotting experiments and monoclonal antibody RHFV1
coupled to Sepharose used to purify plasma and recombinant
factor V molecules were provided by K. G. Mann (Department
of Biochemistry, University of Vermont, Burlington, VT).
Mutagenesis and Transient Expression of Recombinant
Factor V Molecules. The factor V cDNA consists of a 6909 bp
fragment inserted into the pMT2 mammalian expression vector
at the SalI site. Mutant factor V molecules consisting of point
mutations and various deletions of the COOH-terminus of the
heavy chain were synthesized using the QuickChange site-directed
mutagenesis kit(Stratagene,LaJolla,CA) according to the manu-
facturer’s instructions. The mutagenic primers used for the
deletions were 58 bp primers on the sense and antisense strands
oftherecombinantfactorVmolecule.TheprimersforfactorV
5K
were 50-TGAGGCTGAAATTCAGGGATGTTAAATGTAT-
CCCAAAGAAGAAGAAAAAGTCATATGAGATTTTTG-
AACCTCCAGAATC-30 (sense) and 50-GATTCTGGAGGTT-
CAAAAATCTCATATGACTTTTTCTTCTTCTTTGGGAT-
ACATTTAACATCCCTGAATTTCAGCCTCA-30 (antisense).
Primers for factor V
659-663 were 50-AGGCTGAAATTCAGG-
GATGTTAAATGTATCCCATCATATGAGATTTTTGAAC-
CTC-30 (sense) and 50-GAGGTTCAAAAATCTCATATGAT-
GGGATACATTTAACATCCCTGAATTTCAGCCT-30
(antisense). Primers for factor V
5A were 50-GCTGAAATT-
CAGGGATATTAAATGTATCCCAGCGGCGGCGGCGGC-
GTCATATGAGATTTTTGAACCTCCAGA-30 (sense) and
50-TCTGGAGGTTCAAAAATCTCATATGACGCCGCCG-
CCGCCGCTGGGATACATTTAACATCCCTGAATTTCA-
GC-30 (antisense). The mutagenized primers were transformed
into competent Escherichia coli cells, and positive ampicillin-
resistant clones were selected to screen for mutants. Wild-type
factor V and mutant factor V clones were cultured and isolated
using the PureLink Quick Plasmid miniprep kit (Invitrogen,
Carlsbad, CA). The incorporation of the mutations into the
cDNA was verified by DNA sequence analysis, using factor
V-specific primers. Transfection and harvesting of the media
were performed as described in detail by our laboratory (16, 27).
All media containing the recombinant factor V molecules were
concentrated using the Vivaflow 50 Complete System (Vivascience
AG, Hannover, Germany) according to the manufacturer’s
instructions. All recombinant factor V molecules were purified
according to the detailed protocol previously described by our
laboratory (27). The concentration of the recombinant proteins
was determined by an enzyme-linked immunosorbent assay
(ELISA) as previously described (16, 28). The activity and
integrity of the recombinant molecules were verified before and
after activation with thrombin by clotting assays using factor
V-deficient plasma and by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) followed by Western
blotting using both monoclonal and polyclonal antibodies. In
some instances, factor Va fragments were also visualized follow-
ing staining with silver.
Gel Electrophoresis and Western Blotting. SDS-PAGE
analyses of recombinant factor V molecules were performed
using 4 to 12% gradient gels according to the method of
Laemmli (29). Proteins were transferred to polyvinylidene
difluoride (PVDF) membranes according to the method described
byTowbin etal.(30).After the transfer toPVDF,factorVheavy
and light chain(s) were detected using the appropriate mono-
clonal and polyclonal antibodies (31, 32). Immunoreactive frag-
ments were visualized with chemiluminescence. In several instances,
recombinant factor V and factor Va fragments obtained follow-
ing activation of the procofactor with thrombin were visualized
following staining of the gels with silver as described pre-
viously (33).
Analysis of Prothrombin or Recombinant Mutant Pro-
thrombin Activation and FPR-Meizothrombin Cleavage at
Arg
271 by Gel Electrophoresis. Prothrombin or recombinant
1Abbreviations: PS, L-R-phosphatidylserine; PC, L-R-phosphatidyl-
choline; PCPS vesicles, small unilamellar phospholipid vesicles com-
posed of 75% PC and 25% PS (w/w); SDS-PAGE, sodium dodecyl
sulfate-polyacrylamide gel electrophoresis; factor V
WT, wild-type re-
combinant human factor V; factor VaIIa
WT, wild-type recombinant
human factor V activated with R-thrombin; factor V
Δ659-663, recombi-
nant human factor V missing amino acid residues 659-663; factor
VaIIa
Δ659-663,recombinanthumanfactorVmissingaminoacidresidues
659-663 activated with R-thrombin; factor V
5K, recombinant human
factorVwith the
659DDDED
663 f KKKKKmutations;factorVaIIa
5K,
recombinant human factor V with the
659DDDED
663 f KKKKK
mutations activated with R-thrombin; factor V
5A, recombinant human
factor V with the
659DDDED
663 f AAAAA mutations; factor VaIIa
5A,
recombinant human factor V with the
659DDDED
663 f AAAAA
mutations activated with R-thrombin; factor VIIa
PLASMA, plasma-
derived human factor V activated with R-thrombin.Article Biochemistry, Vol. 49, No. 39, 2010 8523
mutant prothrombin molecules (1.4 μM) were incubated with
PCPS vesicles (20 μM), DAPA (50 μM), and factor Va (10-
20 nM) in the presence of 5 mM Ca
2þ in 20 mM Tris and 0.15 M
NaCl(pH7.4).Thereactionwasinitiateduponadditionoffactor
Xa (0.5-1 nM) at room temperature over the time course
indicatedinthefigurelegends.Aliquots(50μL)fromthereaction
mixture were removed at selected time intervals (as indicated in
the figure legends), diluted into 2 volumes of 0.2 M glacial acetic
acid, and concentrated using a Centrivap concentrator attached
to a Centrivap cold trap (Labconco, Kansas City, MO). The
dried samples were dissolved in 0.1 M Tris base (pH 6.8), 1%
SDS, and 1% β-mercaptoethanol, heated for exactly 75 s at
90  C, mixed, and subjected to SDS-PAGE using 9.5% gels
prepared according to the method of Laemmli (29); 6 μgo f
protein per lane was applied. FPR-meizothrombin cleavage at
Arg
271wasassessedinasimilarmannerusing12%SDS-PAGE.
Protein bands were visualized following staining with Coomassie
Brilliant Blue R and destained by diffusion in a methanol/acetic
acid/water solution.
ScanningDensitometryofSDS-PAGEandCalculation
of the Rate of Prothrombin Consumption. Scanning densitom-
etry of the gels was performed as described previously (34).
Briefly, the stained gels were scanned and imported into the
UN-SCAN-ITgel(SilkScientific,Orem,UT).Thenumberswere
normalized to the initial concentration of prothrombin (1.4 μM)
and adjusted for the capability of each fragment to be stained by
Coomassie as described previously (35). Following scanning
densitometry, the data representing prothrombin consumption
as a function of time (seconds) were subsequently plotted using
nonlinear regression analysis and the equation representing a
first-orderexponentialdecayusingPrism(GraphPad,SanDiego,
CA). The apparent first-order rate constant, k (inverse seconds),
obtained directly from the fitted data was divided by the molar
concentration of factor Xa used in each experiment. The number
obtained was subsequently multiplied by the starting concentra-
tionofprothrombin.Thefinalnumbersreportedthroughoutthis
workcharacterizingtheeffectofthemutationsonplasma-derived
prothrombin consumption by prothrombinase assembled with
various recombinant factor Va molecules represent the moles
ofprothrombinconsumed per moleoffactorXapersecondfora
given experiment. The consumption rates reported here are
representative of experiments performed at least in triplicate
usingtwo tofourdifferentpreparationsofrecombinantproteins.
All constants reported in Tables 2 and 3 were extracted directly
from the fitted data. The tables report the standard deviation for
each measurement. In the figure legends, we also provide the
goodness of fit to the equation representing a first-order expo-
nential decay (R
2).
Measurement of Rates of Thrombin Formation in a
Prothrombinase Assay. All factor V molecules, both recom-
binant and plasma, were activated with human R-thrombin as
described previously (36). The assay verifying the activity of the
recombinantmoleculeswasconductedasdescribedbymeasuring
thrombin formation by the change in the absorbance of a
chromogenic substrate at 405 nm (Spectrozyme-TH) monitored
with a Thermomax microplate reader (Molecular Devices,
Sunnyvale, CA) (16, 22). Absorbance at 405 nm was compared
with a standard curve prepared daily using purified thrombin
(0-50 nM).
For the functional calculation of the apparent dissociation
constants (KDapp) between the recombinant factor Va molecules
and factor Xa, experiments were performed in the presence of a
limited concentration of factor Xa (15 pM) and varying con-
centrations of factor Va (between 30 pM and 10 nM). Through-
out the experiments, the assumption was that n was the number
of moles of factor Xa bound per mole of factor Va at saturation;
throughout this study, n = 1, and the stoichiometry of the factor
Va-factor Xa interaction was fixed at 1. The initial rate of
thrombin formation was calculated, and the data were analyzed
and plotted using nonlinear regression analysis and Prism
(GraphPad) according to the one-binding site model. Dissocia-
tion constants reported here were extracted directly from the
fitted data.
The assay using purified reagents and verifying the cofactor
activity of the recombinant factor V molecules for prothrombin
activation was conducted under conditions where all factor
Xa was saturated with factor Va, as described by measuring
R-thrombin formation by the change in the absorbance of a
chromogenic substrate at 405 nm (Spectrozyme-TH, 0.4 mM)
(16). All factor V molecules were activated with thrombin as
described previously (21, 22) .B e c a u s ew ew a n t e dt op r e v e n t
the possibility that differences between prothrombinase as-
sembled with factor Va
WT and prothrombinase assembled
with the three recombinant mutant factor Va molecules may
be attributed to subtle differences in the KDapp of factor Va for
factor Xa, which would result in a smaller amount of pro-
thrombinase formed, all experiments were conducted under
conditions where factor Xa was saturated with factor Va.
Knowing the KDapp of each factor Va species for factor Xa, we
calculated the amount necessary to saturate factor Xa using
the quadratic equation described in the literature (17, 37, 38)
before each experiment. The absorbance was monitored with
a Thermomax microplate reader and compared to that of a
R-thrombin standard prepared daily using purified plasma-
derived R-thrombin. The data were analyzed and plotted using
nonlinearregressionanalysisandPrismaccordingtotheHenri
Michaelis-Menten equation. Kinetic constants provided here
were extracted directly from the fitted data. In addition, in the
figure legends, we report the goodness of fit to the Henri
Michaelis-Menten equation (R
2).
RESULTS
Transient Expression and Activation of Recombinant
Factor V Molecules. To assess the importance of amino acid
region 659-663 from the heavy chain of factor Va, we con-
structed three mutant molecules. We prepared recombinant
factor V
Δ659-663,f a c t o rV
5K, and factor V
5A (Figure 1). Full-
length recombinant factor V
WT and the mutant molecules were
expressed in mammalian cells and purified by immunoaffinity
chromatography as previously described in detail by our labora-
tory (27). All recombinant mutant molecules were activated with
thrombin. Figure 3 illustrates a typical quality control procedure
performed prior to all experiments. Panels A-Cs h o wt h e
subunit composition of the recombinant molecules before and
after activation by thrombin following staining with silver. It is
noteworthy that in all experiments we compare wild-type re-
combinant and plasma factor V to assess if the minute amounts
of impurities present in our recombinant factor V preparations
interfere with cofactor activity. All data obtained with purified
wild-type recombinant factor Va are equivalent and comparable
to the data obtained with a cofactor molecule purified from
pooled normal plasma (Table 1). For the record, our data
obtained with purified recombinant wild-type factor Va are also8524 Biochemistry, Vol. 49, No. 39, 2010 Hirbawi et al.
comparable to the results previously obtained with recombi-
nant mutant factor Va molecules used in conditioned media
(16, 28). Thus, the minimal amounts of impurities present in our
preparations in this study do not interfere with cofactor activity.
In addition, all recombinant factor V molecules that are purified
employing immunoaffinity chromatography using a monoclonal
antibody to factor V are fully active using the experimental
protocol described here [as demonstrated by additional experi-
ments using gel electrophoresis and a polyclonal antibody to
factor V (not shown)]. As shown in Figure 3, following incuba-
tion with thrombin no single chain factor V was apparent on the
gels (most obvious in panel C, lane 2), while fragments with the
expected molecular weights representing the heavy and light
chain of the cofactor appeared. Both of these observations are
consistent with the conclusion that recombinant factor V mole-
cules were fully active using the conditions described in Experi-
mental Procedures. Control experiments demonstrated that
further incubation with thrombin does not result in increased
cofactor activity. In contrast, prolonged incubation of the
recombinant procofactor molecules with thrombin results in
partial inactivation because of cleavage of the heavy chain by
thrombin at Arg
643 as previously demonstrated (27). As a
consequence, the differences in activity observed between the
wild-type or plasma cofactor molecules and the recombinant
mutant factor Va molecules are due to the specific mutations.
SDS-PAGE analyses followed by immunoblotting with specific
monoclonal antibodies to the heavy and light chain of the
cofactor demonstrate that the mutant recombinant proteins are
intact and composed of heavy and light chains that migrated in
accord with their expected molecular weights (panel D).
The recombinant molecules were first assessed for their clot-
tingactivityinatwo-stageclottingassay.Thrombinactivationof
factorV
WTresultedinacofactorwithaclottingactivitysimilarto
that of the plasma-derived molecule (Table 1). Under similar
experimental conditions, factor Va
Δ659-663, factor Va
5K,a n d
factor V
5A displayed ∼3.5-, 11-, and 24-fold less clotting activity,
respectively,thanfactorVa
WT(Table1).Thesedatademonstrate
that amino acid region 659-663 is important for the expression
of optimal factor Va clotting activity.
Kinetic Analyses of Recombinant Factor Va Molecules.
We next examined the capability of the recombinant factor Va
molecules to bind factor Xa and to assemble in prothrombinase
using an assay employing purified reagents and a chromogenic
substrate to probe for thrombin generation. The assay was
performed under conditions of limiting factor Xa concentrations
while the concentration of recombinant factor Va molecules was
varied.Table1providestheresultsofthekineticstudies.Thedata
demonstrate that under the experimental conditions used, factor
Va
WT has a similar affinity for the enzyme, factor Xa, as its
plasma counterpart. Likewise, the three recombinant mutant
factor Va molecules have similar affinities for plasma-derived
factor Xa that are indistinguishable from the affinity of factor
Va
WTforfactorXa.Theseresultsareincompleteaccordwithour
recent findings (20) and demonstrate that the acidic hirudin-like
amino acid regions from the COOH-terminal portion of the
heavy chain of factor Va do not participate in the interaction of
the cofactor with plasma-derived factor Xa (Table 1).
We subsequently evaluated the effect of the mutations on the
Km and kcat of prothrombinase. The raw data are displayed in
Figure 4, while the kinetic constants for each set of titration
derived directly from the fitted data are reported in Table 1.
Under the experimental conditions employed, the mutations had
FIGURE 3: Electrophoreticanalysesofwild-typefactorVandrecom-
binantfactorVmolecules.FactorV
WT,fa ct orV
Δ659-663,fa ct orV
5K,
and factor V
5A were activated with thrombin as described in Experi-
mental Procedures using anti-factor V immunoaffinity chromatog-
raphy and analyzed by SDS-PAGE followed by staining with
silver (A-C): lane 1, factor V prior to activation by thrombin;
lane 2, recombinant molecules following incubation with thrombin.
(D) Following SDS-PAGE and transfer to a PVDF membrane,
immunoreactive fragments were detected with monoclonal anti-
bodies RHFVaHC17 (recognizing an epitope on the heavy chain of the
cofactor between amino acid residues 307 and 506) and RHFVaHC9
(recognizingthelightchain).Attherightofallpanels,thepositionsof
factor V and the heavy and light chains of factor Va are shown.
Table 1: Functional Properties of Various Recombinant Factor Va Molecules
factor Va
species
clotting activity
(units/mg)
a x-fold decrease
b
KDapp
(nM)
c
Km
(μM)
d
kcat
(min
-1)
d,e
kcat/Km
(  10
8 M
-1 s
-1)
x-fold
decrease
f
factor Va
PLASMA 3124(413 - 0.67(0.15 0.26(0.04 2162(55 1.40 -
factor Va
WT 2926(320 - 0.81(0.10 0.23 (0.01 2317(67 1.70 -
factor Va
Δ659-663 823(180 3.5 0.99 (0.22 0.23(0.03 1493( 58 1.08 1.6
factor Va
5K 275(92 11 0.85(0.16 0.28(0.03 1102(25 0.65 2.6
factor Va
5A 120(30 24 0.84(0.10 0.30(0.04 512(20 0.28 6.1
aTwo-stage clotting assays of recombinant factor V molecules was performed as described in Experimental Procedures.
bThe x-fold decrease is the ratio of
the clotting activity of factor Va
WT compared to the clotting activity of the recombinant mutant factor Va molecules.
cApparent dissociation constants of
recombinant factor Va for plasma-derived factor Xa (KDapp) were determined as described in Experimental Procedures at a limiting factor Xa concentration
(15 pM) according to thebinding model assuming one binding site usingPrism.Dissociationconstantswere derived directlyfrom thefitted data.
dTheKmand
kcat of prothrombinase assembled with saturating concentrations of recombinant factor Va molecules were determined as described in Experimental
Procedures according to the Michaelis-Menten equation using Prism. Kinetic constants were derived directly from the fitted data.
ekcat = Vmax/[enzyme]
(in the presence of factor Va); the enzyme concentrations of prothrombinase (factor Xa-factor Va complex on the membrane surface in the presence of Ca
2þ)
were calculated on the basis of the equations previously described in detail in the literature (37, 38). Under the conditions employed, the prothrombinase
concentration was 10 pM.
fThe x-fold decrease is the ratio of the second-order rate constant (kcat/Km) of prothrombinase assembled with factor Va
WT to the
second-order rate constant of prothrombinase assembled with the recombinant mutant factor Va molecules.Article Biochemistry, Vol. 49, No. 39, 2010 8525
no significant effect on the Km of the reaction, while the catalytic
efficiencies of prothrombinase assembled with the three mutant
recombinant cofactor molecules were decreased compared to the
catalytic efficiency of prothrombinase assembled with factor
Va
WT (Figure 4 and Table 1). The data show that prothrom-
binase assembled with factor Va
5K or factor Va
5A has approxi-
mately ∼50 or ∼80% reduced catalytic efficiency, respectively,
when compared to the catalytic efficiency of factor Va
WT,w h i l e
factor Va
Δ659-663 has a ∼40% reduced catalytic efficiency
compared to the value obtained for prothrombinase assembled
with factor Va
WT. Comparison of the second-order rate con-
stant between prothrombinase assembled with the recombinant
mutant cofactor molecules (kcat/Km) and the second-order rate
constant obtained with prothrombinase assembled with factor
Va
WT or factor Va
PLASMA demonstrates that the turnover
number for prothrombinase assembled with the mutant mole-
cules is 40-80% reduced (Table 1). The inability of prothrom-
binase assembled with the mutant cofactor molecules tofunction
optimally coupled to the lackof aneffect of the mutations on the
dissociation constant of the recombinant mutant cofactor mole-
cules for plasma factor Xa can be explained by the inability
of factor Xa within prothrombinase to efficiently convert pro-
thrombintothrombinbecauseofweakenedproductivecollisions
between the enzyme and prothrombin. Overall, the data demonstrate
that amino acid region 659-663 of factor Va heavy chain is
involved in the activation of prothrombin by factor Xa. How-
ever,itisimportanttonotethatwhilethecofactormoleculeshave
a significant deficiency in clotting activity their deficiency in
promoting efficient cleavage of prothrombin when assembled in
prothrombinase, as assessed by an assay using saturating con-
centrationsoffactorVaandachromogenicsubstratetoassessfor
thrombin activity appears to be less pronounced.
Visualization of the Activation Pathway. The findings
obtained thus far indicate that the rate of one or both of the two
prothrombin activation cleavages is impaired when prothrom-
binase is assembled with a cofactor molecule mutated in amino
acid region 659-663 of the heavy chain. To improve our under-
standing ofthereasonforthe deficiencyinprothrombincleavage
by prothrombinase assembled with the recombinant mutant
cofactor molecules, we have studied prothrombin activation by
gelelectrophoresis.Theresults demonstratea delayinprothrom-
bin activation by prothrombinase assembled with either factor
Va
Δ659-663, factor Va
5K,o rf a c t o rV a
5A as compared to the
activation of prothrombin by prothrombinase assembled with
eitherfactorVa
PLASMAorfactorVa
WT(Figure5A-E).Scanning
densitometry of the gels shown in Figure 5 demonstrated 3-, 10-,
and ∼40-fold delays in prothrombin consumption by prothrom-
binase assembled with factor Va
Δ659-663,f a c t o rV a
5K,a n df a c t o r
Va
5A, respectively, compared to the consumption of prothrom-
bin assembled with factor Va
WT or factor Va
PLASMA (Figure 6
and Table 2). The levels of decreased prothrombin consumption
observed correlates very nicely with the results observed in the
clotting assay (Table 1). Prothrombin consumption by pro-
thrombinase assembled with factor Va
5A was most severely
impaired with little meizothrombin visible during the activation
process (Figures 5E). In contrast, when prothrombin is activated
by prothrombinase assembled with either factor Va
Δ659-663 or
factor Va
5K, there is persistence (lingering) of meizothrombin
throughout the activation process. Scanning densitometry of the
gelsshowninpanelsCandDofFigure5demonstratedapeakfor
meizothrombin at 120 s when prothrombin is activated by
prothrombinase assembled with factor Va
WT,w h i l eap e a kf o r
meizothrombin is detected at 200 or 360 s when prothrombin is
activated by prothrombinase assembled with either factor
Va
Δ659-663 or factor Va
5K, respectively (not shown). Overall,
the data strongly suggest that the integrity of amino acid region
659-663 isrequired for optimum rates ofprothrombin activation.
Toimproveourunderstandingoftheeffectofprothrombinase
assembled with factor Va
5A on prothrombin activation, we
compared prothrombin activation by factor Xa alone or by
membrane-bound factor Xa, or by prothrombinase assembled
withfactorVa
5Aovera3htimeperiod(Figure7A-D). Thedata
demonstrate that very little thrombin is produced by factor Xa
alone (panel A) or by membrane-bound factor Xa (panel B). In
the presence of prothrombinase assembled with factor Va
5A
(panel C), both intermediates, meizothrombin and prethrombin-2,
are observed. Scanning densitometry of the gel shown in
Figure 7C demonstrated a rate of prothrombin consumption by
prothrombinase assembled with factor Va
5A similar to the rate
observed in Figure 5D (Table 2). Altogether, these data are in
complete accord with the findings obtained in the functional
assays, and the combined data suggest that both prothrombin
activation cleavages (Arg
320 and Arg
271) appear to be affected
when prothrombinaseisassembled witheither factorVa
Δ659-663,
factor Va
5K,o rf a c t o rV a
5A. Overall, the data demonstrate that
amino acidregion 659-663 activelyparticipates inthe activation
FIGURE 4: Determination of the kinetic parameters of prothrom-
binase assembled with the various recombinant factor Va species.
Thrombin generation experiments were conducted as described in
Experimental Procedures by varying the substrate concentration
(from 25 nM to 4 μM) in the presence of 10 pM factor Xa. Factor
V
WT,f a c t o rV
PLASMA,f a c t o rV
Δ659-663,f a c t o rV
5K, and factor V
5A
were activated with thrombin as described in Experimental Proce-
dures. The solid lines represent the nonlinear regression fits of the
datausingPrismaccordingtotheHenriMichaelis-Mentenequation
(Vo = Vmax[prothrombin]/Km þ [prothrombin]) to yield the Km and
kcat (kcat = Vmax/Etotal,w h e r eEtotal is the concentration of
prothrombinase) (Table 1). Prothrombinase was assembled with
recombinant factor Va
WT [20 nM (2); R
2 = 0.95], factor Va
PLASMA
[20 nM (b); R
2 = 0.96], factor Va
Δ659-663 [20 nM (9): R
2 =0 . 9 4 ] ,
factor Va
5K [20 nM (0); R
2 = 0.97], and factor Va
5A [20 nM (3);
R
2 = 0.94]. The data for factor Va
WT,f a c t o rV a
PLASMA,f a c t o r
Va
Δ659-663,andfactorV
5Kshowtheaverageresultsobtainedfromat
least three different titrations with three different preparations of
purified proteins. The data for factor Va
5A are representative of six
different titrations using five different preparations of recombinant
protein.KineticconstantsreportedinTable1wereextracteddirectly
from the fitted data.8526 Biochemistry, Vol. 49, No. 39, 2010 Hirbawi et al.
of prothrombin by prothrombinase, and that the nature of the
mutations in this region has a differential effect on the pathway
and rate of prothrombin activation by prothrombinase.
Activation of Recombinant Mutant Prothrombin by
Prothrombinase Assembled with Mutant Factor Va Mole-
cules. The data obtained thus far in the study of plasma-derived
prothrombin activation by prothrombinase assembled with the
mutant cofactor molecules demonstrate that (1) meizothrombin
lingers throughout the time course when prothrombin is acti-
vated by prothrombinase assembled with the mutant cofactor
molecules and (2) the appearance of the B chain of thrombin
is also delayed. To verify which cleavage in prothrombin is
specifically affected by each of the modifications in amino acid
region 659-663 of factor Va heavy chain, we used prothrombin
molecules that cannot be cleaved at either Arg
271 [rMZ-II
(Figure 8)] or Arg
320 [rP2-II (Figure 9)] (26).
Our findings demonstrate a significant difference between the
rates of activation of rMZ-II by prothrombinase assembled with
eitherfactorVa
Δ659-663,factorVa
5K,orfactorVa
5Aascompared
totheratesofrMZ-IIcleavageandactivationbyprothrombinase
madewithfactorVa
WTor factorVa
PLASMA (Figure 8). Scanning
densitometry of the gels shown in Figure 8 demonstrates that
cleavage at Arg
320 of rMZ-II is delayed by ∼2-fold when
prothrombinase is assembled with factor Va
Δ659-663 and 4-fold
when prothrombinase is assembled with factor Va
5K compared
tocleavage ofthe recombinant mutant prothrombin moleculeby
FIGURE 5: Analysis of the activation of plasma-derived prothrombin by prothrombinase assembled with various mutant factor Va molecules.
Plasma-derivedprothrombin(1.4μM)wasincubatedindifferentmixtureswithPCPSvesicles(20μM)and(AandB)prothrombinaseassembled
witheitherfactorVa
WT[finalconcentrationof20nM,96.6%factorXasaturation(A)]orfactorVa
PLASMA[finalconcentrationof20nM,95.6%
factorXasaturation(B)] asdescribedinExperimentalProcedures,(C) prothrombinaseassembledwithfactorVa
Δ659-663 (final concentration of
20nM,95.1%factorXasaturation),(D)prothrombinaseassembledwithfactorVa
5K(finalconcentrationof20nM,95.7%factorXasaturation),
and(E)prothrombinaseassembledwithfactorVa
5A(finalconcentrationof30nM,97.2%factorXasaturation).Thereactionswerestartedbythe
additionoffactorXa(1nM).Atselectedtimeintervals,aliquotsofthereactionmixtureswerewithdrawnandtreatedasdescribedinExperimental
Procedures. Lane M contained the molecular weight markers (from top to bottom): 98000, 64000, 50000, and 36000, respectively. Lanes 1-19
containedsamplesfromthereactionmixturebefore(0min)theadditionoffactorXaand20s,40s,60s,80s,100s,120s,140s,160s,180s,200s,
220s,240s,5min,6min,10min,20min,30min,and60min,respectively,aftertheadditionoffactorXa.(F)Meizothrombinpathway.Schematic
structure of fragments derived following prothrombin activation by prothrombinase via two sequential cleavages: initial cleavage at Arg
320
followed by cleavage at Arg
271. Prothrombin is composed of an NH2-terminal domain containing 10 γ-carboxyglutamic acid residues (yellow),
two kringle domains (blue), and a COOH-terminal serine protease domain (red). The prothrombin-derived fragments identified on the gels are
shownasfollows:II,prothrombin(aminoacidresidues1-579);F132-A,fragment132-Achain(aminoacidresidues1-320);F132,fragment132
(amino acid residues 1-271); B, B chain of R-thrombin (amino acid residues 321-579); F1, fragment 1 (amino acid residues 1-155). Secondary
cleavagesatArg
155andArg
284(dottedgreenarrows)areproducedbyeitherthrombinormembrane-boundfactorXa.ThefactorVaspeciesused
for the reconstitution of prothrombinase are shown under each panel.Article Biochemistry, Vol. 49, No. 39, 2010 8527
prothrombinase assembled with factor Va
WT (Table 2 and
Figure 10A). In contrast, very slow prothrombin consumption
was observed when rMZ-II was incubated with prothrombinase
assembled with factor Va
5A (Figure 8E). The rate of cleavage of
rMZ-IIbyprothrombinaseassembledwithfactorVa
5Ais33-fold
slower than the rate of cleavage of rMZ-II by prothrombinase
assembled with factor Va
WT (Table 2). These data confirm our
findings obtained with plasma-derived prothrombin. In partic-
ular, the data obtained with factor Va
5A and rMZ-II verify the
data shown in Figures 5E and 7C obtained with plasma-derived
prothrombin and factor Va
5A, demonstrating slow cleavage of
prothrombin at Arg
320 byprothrombinase assembled withfactor
Va
5A. Overall, the data demonstrate that prothrombinase-
mediated cleavage at Arg
320 in prothrombin is affected by
modifications in amino acid region 659-663 of factor Va heavy
chain.
ThedatashowninFigures9and10BandTable3demonstrate
that the rate of cleavage of rP2-II at Arg
271 by prothrombinase
assembled with either factor Va
Δ659-663,f a c t o rV a
5K, or factor
Va
5A is very slow compared to the rate of cleavage of rP2-II at
Arg
271 by prothrombinase assembled with either factor Va
WT or
factor Va
PLASMA. However, it is important to note that while
under the conditions described in the legend of Figure 9, pro-
thrombin was slowly consumed by prothrombinase assembled
with the mutant cofactor molecules (Table 3), and a rate of
prothrombin consumption could not be obtained from the gels
shown in panels C-E. Overall, the data shown in Figures 5-10
demonstrate that mutations in acidic amino acid segment
659-663 of factor Va differentially affect the rate of cleavage
ofthe two activatingcleavage sites ofprothrombinbyprothrom-
binase. These data unambiguously demonstrate that this portion
of factor Va heavy chain plays a role in controlling the catalytic
efficiency of factor Xa within prothrombinase for prothrombin
activation.
Activation of FPR-Meizothrombin by Prothrombinase
Assembled with Mutant Factor Va Molecules. Analysis of
the results obtained thus far with plasma-derived and recombi-
nant prothrombin suggests that activation of the molecules by
prothrombinase assembled with factor Va
Δ659-663,f a c t o rV a
5K,
and factor Va
5A is impaired compared to cleavage of the recom-
binant prothrombin molecules by prothrombinase assembled
with factor Va
WT because of delayed cleavages at both Arg
320
and Arg
271 resulting inbothslow prothrombin consumption and
less conversion of meizothrombin to thrombin. In addition, our
data show that the rate of cleavage at Arg
271 of rP2-II appears to
beaffectedmorethantherateofcleavageatArg
320ofrMZ-II,by
prothrombinase assembled with the mutant cofactor molecules.
It has been shown that a change in the conformation of
meizothrombin (ratcheting) is associated with cleavage of pro-
thrombin at Arg
320 (39). To ascertain the effect of the mutations
of the factor Va heavy chain on the cleavage of prothrombin at
Arg
271 following the transition that occurs after cleavage at
FIGURE 6: Analysis of prothrombin consumption by prothrom-
binase assembled with recombinant factor Va molecules. The gels
shown in Figure 5 were scanned, and prothrombin consumption
was recorded as described in Experimental Procedures. Following
scanning densitometry, the numbers were normalized to the initial
concentration of prothrombin (1.4 μM). The data representing
prothrombin consumption (micromolar) as a function of time
(seconds) were subsequently plotted using nonlinear regression anal-
ysis according to the equation representing a first-order exponential
decay using Prism (GraphPad). Prothrombinasewas assembled with
recombinant factor Va
WT [(2) R
2= 0.99], factor Va
PLASMA [(b) R
2=
0.99], factor Va
Δ659-663 [(9) R
2 = 0.99], factor Va
5K [(0) R
2 =
0.94], and factor Va
5A [(3) R
2 = 0.98]. The apparent first-order rate
constant, k(inverse seconds), obtained directly from the fitted data was
d i v i d e db yt h em o l a rc o n c e n t r a t i o no ff a c t o rX au s e di ne a c he x p e r i -
ment.Thenumberobtainedwassubsequentlymultiplied bythe starting
concentration of prothrombin. The resulting numbers representing
prothrombin consumption are listed in Table 2. The inset represents
the progress of the reaction during the first 10 min.
Table 2: Rate of Activation of Native Plasma-Derived Prothrombin and Recombinant Mutant rMZ-II in the Presence of Prothrombinase Assembled with
Various Recombinant Factor Va Species
enzyme
plasma-derived prothrombin
a
(initial cleavage at Arg
320)
[mol consumed s
-1 (mol of factor Xa)
-1]
rMZ-II
a
(cleavage at Arg
320)
[mol consumed s
-1 (mol of factor Xa)
-1]
factor Xa 0.065( 0.025 0.0235(0.017
b
prothrombinase with factor Va
PLASMA 19.0(1.5 14.8 (0.8
prothrombinase with factor Va
WT 21.8(1.9 11.2( 0.8
prothrombinase with factor Va
Δ659-663 7.7(0.5 6.6(0.7
prothrombinase with factor Va
5K 2.1(0.4 2.9( 0.8
prothrombinase with factor Va
5A 0.58(0.1
c/0.18(0.06
d 0.34( 0.1
aThe rates of plasma-derived prothrombin and recombinant mutant prothrombin rMZ-II consumption were obtained following scanning densitometry of
gels shown in Figures 5 and 8, respectively. The final rate of prothrombin consumption in the presence of prothrombinase assembled with various factorV a
species was extracted following plotting of the data according to the equation representing a first-order exponential decay as described in Experimental
Procedures (Figures 6 and 10A). The apparent first-order rate constants were obtained directly from the fitted data.
bRate obtained from a time course using
10nMfactorXa(R
2=0.922).
cFromthe1htimecoursewith20nMfactorVa
5Aand1nMfactorXa[R
2=0.985(Figure5)].
dFromthe3htimecourse20nM
factor Va
5A and 0.5 nM factor Xa [R
2 = 0.987 (Figure 7)].8528 Biochemistry, Vol. 49, No. 39, 2010 Hirbawi et al.
Arg
320, we compared the rate of cleavage of FPR-meizothrombin
by prothrombinase assembled with either factor Va
WT or the
recombinant mutant cofactor molecules (Figure 11). The data
demonstrate a delay in cleavage of FPR-meizothrombin at Arg
271
by prothrombinase assembled with factor Va
Δ659-663 (panel B),
factor Va
5K (panel C), or factor Va
5A (panel D) as compared to the
same reaction catalyzed by prothrombinase assembled with factor
Va
WT (panel A). Quantitative scanning densitometry of fragment
132-A present on the gels shown in Figure 11 demonstrated an
∼2-fold delay in the cleavage of FPR-meizothrombin at Arg
271 by
prothrombinase assembled with all mutant cofactor molecules,
compared to cleavage at Arg
271 by prothrombinase assembled with
factor Va
WT (Figure 12 and Table 3). However, the rates for
cleavage of FPR-meizothrombin at Arg
271 are2-fold faster than the
rate of cleavage of FPR-meizothrombin by factor Xa alone. Thus,
while mutations in hirudin-like region 659-663 of factor Va have a
differential effect on the rate of cleavage at Arg
320,d e l e t i o no r
substitutions of amino acid residues within the same region have a
similar effect on prothrombinase, namely, considerably impeding
the acceleration of the rate of cleavage at Arg
271 of meizothrombin
attributed to the interaction of factor Va with factor Xa (3, 40).
Thesedataareincompleteagreementwithallthefindingspresented
herein and overall demonstrate that the
659DDDED
663 amino acid
sequence from the factorVa heavy chain ispartofagroupofamino
acids that regulate the rate of thrombin formation during activation
of prothrombin by prothrombinase.
DISCUSSION
The data presented here using recombinant proteins demon-
strate for the first time that the acidic region composed of amino
acids659-663locatedattheCOOH-terminusoffactorVaheavy
chain is important for coordinated activation of prothrombin by
prothrombinase, resulting in timely thrombin formation at the
place of vascular injury. To the best of our knowledge, this is
the first time that the roleofthisspecificamino acidregion of the
cofactor has ever been investigated. Our data demonstrate the
order factor Va
Δ659-663 >f a c t o rV a
5K >f a c t o rV a
5A with
respect to retention of clotting and that prothrombinase as-
sembled with factor Va
Δ659-663 is a better enzyme than pro-
thrombinaseassembledwithfactorVa
5K,whichinturnisabetter
enzyme than prothrombinase assembled with factor Va
5A for
prothrombin activation. These data strongly suggest a differen-
tial effect of the mutations within amino acid region 659-663 of
factor Va heavy chain on the rate of the two prothrombin
activating cleavage sites. It is noteworthy that our data strongly
suggest that deletion of a portion of factor Va to test its overall
function withinthe cofactor moleculebyfunctional assaysalone,
without analyzing the pathway to thrombin formation, does not
represent optimal experimental conditions, required to obtain a
definite answer. Our findings assign an important physiological
role to the acidic hirudin-like region 659-663 from the COOH-
terminus of factor Va heavy chain for efficient prothrombin
activation. Namely, the
659DDDED
663 amino acid sequence is
partofagroupofaminoacidsthatregulatetherateofcleavageof
prothrombin byprothrombinaseat both Arg
320 and Arg
271. This
acidic pentapeptide together with the
695DYDYQ
699 se-
quence (20, 22, 23) are both located on the surface of the factor
Va molecule (41) and are conserved among species (Figure 2),
attesting to their physiological significance. Because both amino
acid sequences have no effect on the direct interaction between
factor Va and factor Xa, our findings are consistent with the
FIGURE 7: Analysis of the activation of plasma-derived prothrombin by prothrombinase assembled with factor Va
5A over an extended time
period. (A) Plasma-derived prothrombin (1.4 μM) was incubated with factor Xa (10 nM). (B) Plasma-derived prothrombin (1.4 μM) was
incubated with PCPS vesicles (20 μM) and factor Xa (0.5 nM). (C) Plasma-derived prothrombin (1.4 μM) was incubated with PCPS vesicles
(20μM),factorXa(0.5nM),andfactorVa
5A(finalconcentrationof20nM,96%factorXasaturation).Allreactionswerestartedbytheaddition
of factor Xa. At selected time intervals, aliquots of the reaction mixtures were withdrawn and treated as described in Experimental Procedures.
Lane M contained the molecular weight markers (from top to bottom): 98000, 64000, 50000, and 36000, respectively. Lanes 1-19 contained
samples from the reaction mixture before (0 min) the addition of factor Xa and 30 s, 60 s, 3, min, 5 min, 7 min, 10 min, 12 min, 15 min, 20 min,
25 min, 45 min, 60 min, 75 min, 90 min, 105 min, 120 min, 150 min, and 180 min, respectively, after the addition of factor Xa. (D) Schematic
representationoffragments derived following prothrombin activationbyprothrombinasevia two sequentialcleavages:initial cleavageatArg
271
followedbycleavageatArg
320.Theprothrombin-derivedfragmentidentifiedonthegelsinadditiontothefragmentsdescribedinFigure5FisP2,
prethrombin-2 (amino acid residues 272-579).Article Biochemistry, Vol. 49, No. 39, 2010 8529
interpretation that these acidic amino acid sequences contribute
significantly to the macromolecular substrate recognition of
prothrombin by prothrombinase and demonstrate that factor
Va indeed regulates the activity of factor Xa within the enzymatic
complex.
Factor Va
Δ659-663,f a c t o rV a
5K, and factor Va
5A exhibited a
significantdecreaseinclottingactivitycomparedtotheactivityof
factor Va
WT. While factor Va
Δ659-663 has 3.5-fold less clotting
activity than the wild-type cofactor molecule, factor Va
5A has
24-fold less clotting activity than factor Va
WT. Gel electrophoresis
analyses demonstrated that the recombinant molecules are im-
paired in their clotting activity because of the inability of pro-
thrombinase assembled with the recombinant cofactor molecules
to generate thrombin efficiently. Data obtained with plasma-
derived prothrombin showed a delay in prothrombin consump-
tion when prothrombinase was assembled with either factor
Va
Δ659-663,f a c t o rV a
5K,o rf a c t o rV a
5A, compared to plasma-
derived prothrombin activation by prothrombinase assembled
with factor Va
WT. Similarly, experiments using recombinant
mutant prothrombin molecules demonstrate that while cleavage
at Arg
320 and rMZ-II consumption are delayed significantly when
prothrombinase is assembled with factor Va
Δ659-663,f a c t o rV a
5K,
and factor Va
5A, cleavage at Arg
271 and rP2-II consumption are
significantly inhibited compared to cleavage of rMZ-II and rP2 by
prothrombinase assembled with factor Va
WT.I nc o n t r a s t ,c l e a -
vage at Arg
271 of FPR-meizothrombin is comparable with pro-
thrombinase assembled with all recombinant mutant mole-
cules and approximately 2-fold slower than cleavage of the
same molecule by prothrombinase assembled with factor
Va
WT. It is important to note that the maximum increase in
the rate of cleavage of meizothrombin at Arg
271 by prothrom-
binase assembled with factor Va
PLASMA or factor Va
WT as
compared to cleavage of the molecule by factor Xa alone is
4-fold (3, 40). This fact is clearly illustrated by our findings
shown in Table 3 where the rate of FPR-meizothrombin
consumption by factor Xa alone is approximately 4-fold
slower that the rate of FPR-meizothrombin consumption by
prothrombinase assembled with factor Va
WT. Thus, a 2-fold
decrease in the rate of FPR-meizothrombin consumption by
prothrombinase assembled with the mutant molecules repre-
sents a significant decrease in the activity of prothrombinase
(i.e., 50% of the maximum effect observed).
Our findings demonstrate that acidic amino acid region
659-663 from factor Va is not involved in the interaction of
the cofactor with factor Xa. In addition, we show that (in
prothrombinase) factor Va
5A-mediatedactivation ofprothrombin
is associated with little meizothrombin accumulation (Figure 5E).
However, efficient initial cleavage at Arg
320 by prothrombinase
assembled with factor Va
5A can be easily detected (Figures 8
and 10A). These data suggest that cleavage of meizothrombin at
Arg
271 may be faster than the initial cleavage of prothrombin at
Arg
320. Accumulation of prethrombin-2 (observed in Figures 5E
and 7C) indicates that initial cleavage at Arg
271 can occur but does
not indicate that it must occur first. In fact, the rate of cleavage of
prothrombin at Arg
320 by prothrombinase assembled with factor
Va
5A is substantial (Figure 8E) and comparable to the rate of
prothrombin cleavage by prothrombinase assembled with factor
Va
5K (Figure 8D), using rMZ-II as the substrate. On the other
FIGURE 8: Electrophoretic analyses of the activation of rMZ-II by prothrombinase assembled with mutant factor Va molecules. rMZ-II was
incubatedindifferentmixtureswithPCPSvesicles,DAPA,andvariousfactorVamolecules.ThereactionwasstartedbytheadditionoffactorXa
(0.5nM),andthesamplesweretreatedasdetailedinExperimentalProcedures.ThegelswerescannedandquantifiedasdetailedinExperimental
Procedures.Lanes 1-9 contained samples ofthe reactionmixturefollowing incubation ofprothrombinasewithrMZ-IIbefore(lane1) and after
incubation for 1, 3, 5, 10, 20, 45, 60, and 120 min with factor Xa, respectively: (A) prothrombinase assembled with factor Va
WT (20 nM),
(B) prothrombinase assembled with plasma-derived factor Va (20 nM), (C) prothrombinase assembled with factor Va
Δ659-663 (20 nM),
(D) prothrombinase assembled with factor Va
5K (20 nM), and (E) prothrombinase assembled with factor Va
5A (20 nM). (F) Schematic of the
recombinant prothrombin moleculeused(rMZ-II). This moleculeisa triplemutantwithonlyone cleavage site for prothrombinaseremaining at
Arg
320.Positions ofprothrombin-derived fragmentsareindicated attheright asdetailedinthelegends ofFigures 5 and 7.The timecourses were
extendedforupto2hforthetitrationofeachprothrombinmolecule,andthedatawereusedtocalculatetheconsumptionrateineachexperiment
(illustrated in Figure 10A and reported in Table 2). The factor Va species used for the reconstitution of prothrombinase are shown under
each panel.8530 Biochemistry, Vol. 49, No. 39, 2010 Hirbawi et al.
hand, all of the mutants seem profoundly impaired to a similar
extentwithrespecttopromotingcleavageatArg
271usingsubstrate
rP2-II (Figure 9). Therefore, factor Va
5A does not seem to be very
exceptional compared to the other mutants with respect to
preferred cleavage sites. The data obtained with prothrombinase
assembled with factor Va
5A and the recombinant prothrombin
mutants instead support the usual pathway through meizothrom-
bin, with a preference for initial cleavage after Arg
320. Conse-
quently, the combined data suggest that failure of meizothrombin
to accumulate during activation of prothrombin by prothrom-
binase assembled with factor Va
5A could be explained by the fact
that the rate of cleavage at Arg
271 is much faster acting on
FIGURE 9: Electrophoretic analyses of the activation of rP2-II by prothrombinase assembled with mutant factor Va molecules. rP2-II was
incubatedindifferentmixtureswithPCPSvesicles,DAPA,andvariousfactorVamolecules.ThereactionwasstartedbytheadditionoffactorXa
(0.5nM),andthesamplesweretreatedasdetailedinExperimentalProcedures.ThegelswerescannedandquantifiedasdetailedinExperimental
Procedures. Lanes 1-9 contained samples of the reaction mixture following incubation of prothrombinase with rP2-II before (lane 1) and after
incubation for 1, 3, 5, 10, 20, 45, 60, and 120 min with factor Xa, respectively: (A) prothrombinase assembled with factor Va
WT (20 nM),
(B) prothrombinase assembled with plasma-derived factor Va (20 nM), (C) prothrombinase assembled with factor Va
Δ659-663 (20 nM),
(D) prothrombinase assembled with factor Va
5K (20 nM), and (E) prothrombinase assembled with factor Va
5A (20 nM). (F) Schematic of the
recombinant prothrombin molecule used (rP2-II). This molecule is a triple mutant with only one cleavage site for prothrombinase remaining at
Arg
271.Positions ofprothrombin-derived fragmentsareindicated attheright asdetailedinthelegends ofFigures 5 and 7.The timecourses were
extendedforupto2hforeachprothrombinmolecule,andthedatawereusedtocalculatetheconsumptionrateineachexperiment(illustratedin
Figure 10B and reported in Table 3). The factor Va species used for the reconstitution of prothrombinase are shown under each panel.
FIGURE 10: Analysis of recombinant prothrombin consumption by prothrombinase assembled with recombinant factor Va molecules. The gels
shown in Figures 8 and 9 were scanned, and prothrombin consumption was recorded as described in Experimental Procedures. Following
scanning densitometry, the data representing recombinant mutant prothrombin consumption as a function of time (seconds) were plotted using
nonlinear regression analysis according to the equation representing a first-order exponential decay using Prism (GraphPad) as described in the
legend ofFigure 6. Prothrombinasewas assembled withrecombinant factor Va
WT(2), factor Va
PLASMA (b), factorVa
Δ659-663 (9), factor Va
5K
(0), and factor Va
5A (3). The apparent first-order rate constant, k (inverse seconds), was obtained directly from the fitted data. The resulting
numbersrepresentingrecombinantmutantprothrombinconsumptionarereportedinTables2and3.PanelAshowsthedataobtainedfollowing
cleavageofrMZ-II:factorVa
WT,R
2=0.99;factorVa
PLASMA,R
2=0.99;factorVa
Δ659-663,R
2=0.99;factorVa
5K,R
2=0.99;andfactorVa
5A,
R
2 = 0.98. The time course was conducted over a period of 2 h; however, for the purpose of graphing, only the data points for the first hour are
shown. (B) shows the data obtained following cleavage of rP2-II: factor Va
WT, R
2 = 0.99; and factor Va
PLASMA, R
2 =0 . 9 8 .Article Biochemistry, Vol. 49, No. 39, 2010 8531
meizothrombin than on prothrombin or rP2-II. Overall, our data
strongly suggest that the deficiency of all recombinant mutant
factor Va molecules in directing efficient prothrombin consump-
tion by factor Xa within prothrombinase is due to the inability
of the mutant cofactors to provide a productive interaction of
the enzyme with prothrombin as previously demonstrated
(7, 10, 18, 42, 43) because of the lack of the acidic segment
composed of amino acids 659-663.
Initial cleavage of prothrombin at Arg
320 by prothrombinase
and generation of meizothrombin is absolutely dependent on the
incorporation of factor Va into the enzymatic complex and its
interaction with factor Xa and prothrombin on a membrane
surface. Itis thus assumedthat once factor Va binds to factor Xa
ontheprocoagulantmembrane surface,the complexwillinteract
with an exosite on prothrombin that in turn will facilitate
cleavage at Arg
320 exclusively (44, 45). Therefore, from the
published data, it has been inferred for some time that the
productive docking of prothrombinase on prothrombin, under
conditions where factor Va is in large excess over factor Xa
[conditions mimicking the propagation phase of coagulation (46)],
will result in fast and efficient cleavage at Arg
320,w i t ht h r o m b i n
formationthroughthemeizothrombinpathway.Thedatashown
inFigures5-8demonstratethatprothrombinaseassembledwith
factor Va
Δ659-663, factor Va
5K,a n df a c t o rV a
5A (under condi-
tions that would promote activation of prothrombin exclusively
through the meizothrombin pathway) are impaired in their
Table 3: Rates of Activation of Recombinant Prothrombin rP2-II and Plasma-Derived FPR-Meizothrombin in the Presence of Prothrombinase Assembled
with Various Recombinant Factor Va Species
enzyme
rP2-II
a (cleavage at Arg
271)
[mol consumed s
-1 (mol of factor Xa)
-1]
FPR-meizothrombin
a (cleavage at Arg
271)
[mol of fragment 132-A consumed s
-1 (mol of factor Xa)
-1]
factor Xa 0.048(0.012
b 13.5( 2.3
c
prothrombinase with factor Va
PLASMA 3.4(0.5 42.6 (7
c
prothrombinase with factor Va
WT 3.6(0.5 52.2( 14
prothrombinase with factor Va
Δ659-663 NR
d 23.5(2.1
prothrombinase with factor Va
5K NR
e 20.1(4.3
prothrombinase with factor Va
5A NR
f 26.1(2.2
aRates of rP2-II consumption in the presence of wild-type or plasma factor Va and recombinant mutant factor Va
Δ659-663, factor Va
5K, and factor Va
5A
were measured following scanning densitometry of gels shown in Figure 9. Calculation of the apparent first-order rate constant was achieved as detailed in
Experimental Procedures. The rate of fragment 132-A consumption in the presence of prothrombinase assembled with factor Va
WT, factor Va
Δ659-663, factor
Va
5K, or factor Va
5A was measured following scanning densitometry of the gels shown in Figure 11 and calculation of the apparent first-order rate constant as
detailed in Experimental Procedures. The rates of rP2-II and fragment 132-A consumption were extracted from the fitted data (shown in Figures 10B and 12,
respectively).
bRate obtained from a time course using 10 nM factor Xa (R
2 = 0.975).
cFrom ref 20 (R
2 = 0.97 for both sets of data).
dNo rate could be
obtained. The concentration of rP2-II varied from 1400 nM at time zero to 1250 nM following a 2 h incubation with prothrombinase assembled with factor
Va
Δ659-663.
eNo rate could be obtained. The concentration of rP2-II varied from 1400 nM at time zero to 1200 nM following a 2 h incubation with
prothrombinaseassembledwithfactorVa
5K.
fNoratecouldbeobtained.TheconcentrationofrP2-IIvariedfrom1400nMattimezeroto1100nMfollowinga
2 h incubation with prothrombinase assembled with factor Va
5A.
FIGURE 11: GelelectrophoresisanalysesforcleavageofFPR-meizothrombin.FPR-meizothrombin(1.4μM)wasincubatedindifferentmixtures
withPCPS vesicles (20μM) and factorVa asdescribed inthe legend ofFigure5.The reactions were started bythe addition offactorXa, and the
samples werefurther treated, scanned,and quantifiedasdetailedinExperimentalProcedures: (A) factor Va
WT, (B) factorVa
Δ659-663, (C) factor
Va
5K, and (D) factor Va
5A. LaneM contained the molecularweightmarkers (fromtop tobottom): 50000,36000,and 22000,respectively. Lanes
1-19containedsamplesfromthereactionmixturebefore(0min)theadditionoffactorXaand20s,40s,60s,80s,100s,120s,140s,160s,180s,
200 s, 220 s, 240 s, 5 min, 6 min, 10 min, 20 min, 30 min, and 60 min, respectively, after the addition of factor Xa. The prothrombin-derived
fragments are shown as detailed in the legend of Figure 5. The recombinant factor Va species used for the reconstitution of prothrombinase are
shown under each panel.8532 Biochemistry, Vol. 49, No. 39, 2010 Hirbawi et al.
ability to support the initial cleavage of prothrombin at Arg
320.
The data shown in Figures 9-12 also demonstrate that pro-
thrombinase assembled with the mutant recombinant factor Va
molecules are also impaired in their ability to cleave at Arg
271 of
either rP2-II or FPR-meizothrombin. These results placed in the
context of the literature demonstrate that upon its incorporation
into prothrombinase factor Va, rather than providing an exosite
for prothrombin necessary for exclusive cleavage at Arg
320,i s
required to actively guide factor Xa though the activation
process. We must thus conclude that depending on the quality
and concentration of factor Va during the initiation of clot
formation, once prothrombin has engaged its exosite(s) on
prothrombinase, the enzyme will cleave the substrate at either
Arg
320 or Arg
271 with optimal rates (47). As a consequence, it
appears that it is not the extended exosite for prothrombin on
prothrombinase per se that promotes acceleration of the rate of
prothrombin activation by specifically directing the initial cleav-
age at Arg
320 and meizothrombin formation, but it is rather the
incorporation of factor Va into the complex that produces a
rearrangement of the components of the enzymatic complex,
resulting in an increase in the rate of cleavage at both Arg
320 and
Arg
271 by factor Xa.
The effects observed in our study with the mutant cofactor
molecules are significant and comparable when using clotting
assays and when studying prothrombin activation. It has been
well established that cleavage of prothrombin at Arg
271 has an
importanteffecton the progressive formationofthe active siteof
thrombin (8, 48), and that meizothrombin has a higher amido-
lytic activity than thrombin toward several chromogenic sub-
strates usually employed to assess thrombin esterase activity
(25, 49-51). In addition, it has been demonstrated following
analysis of the crystal structure of meizothrombin, that ABE-II
ofmeizothrombin has not yet beenexposed, because it iscovered
by fragment 2 (9). This fact alone explains the poor clotting
activity of meizothrombin because ABE-II is part of the binding
site of thrombin for fibrinogen and is required for optimal rates
of fibrin formation during blood clotting. ABE-II is exposed
following cleavage of meizothrombin at Arg
271 and release of
fragment 2. We show that the catalytic activity of prothrom-
binase when assembled with the mutant cofactor molecules is
only moderately affected by the mutations, when the activity of
factor Va is measured in an assay using a chromogenic substrate
toassessthrombinactivity.Indeed,thekcatandsecond-orderrate
constants of prothrombinase assembled with the mutant factor
Va molecules are approximately 20-60% of that of prothrom-
binase assembled with factor Va
PLASMA or factor Va
WT.I n
contrast, the clotting activity of the mutant cofactor molecules
is severely impaired (11- and 24-fold decreased clotting activity
with factor Va
5K and factor V
5A, respectively), and gel electro-
phoresis experiments combined with densitometric analyses
reveal a similar and significant delay in prothrombin activation
(10- and 38-fold decreased rates of prothrombin consumption
withprothrombinaseassembledwithfactorVa
5KandfactorV
5A,
respectively), with meizothrombin being more stable throughout
the activation process when prothrombinase is assembled with
factor Va
5K as compared to prothrombin activation by pro-
thrombinase assembled with either factor Va
WT or factor
Va
PLASMA. The findings presented here are entirely consistent
with earlier findings obtained with plasma-derived pro-
teins (52-54), recent findings obtained with recombinant pro-
teins(42),andourdata(20,21).Explicitly,whenprothrombinase
is assembled with a factor Va molecule possessing a heavy chain
that is truncated at the acidic hirudin-like COOH-terminal
region, a discrepancy is observed between the activity of factor
Vameasuredbytheclottingassayandtheactivityofthecofactor
measured in an assay using a chromogenic substrate to assess
thrombinactivity.Thisdiscrepancyisnotduetotheexperimental
conditions used since when using purified reagents and a
chromogenic substrate to measure thrombin activity, our experi-
mental conditions were chosen carefully to mimic similar condi-
tions obtained physiologically during clotting [7 pmol of pro-
thrombinaseformedatclottingtime(55)comparedto10pmolof
prothrombinase used in the experiments used to calculate the
kineticconstants (Figure4 andTable 1)]. The dataprovided here
and in our recent manuscript detailing the properties of factor
V
Δ680-709 (20) explain these paradoxical findings. Because we
have studied plasma-derived prothrombin, rMZ-II, rP2-II, and
FPR-meizothrombin activation by gel electrophoresis, we can
conclude that meizothrombin lingers throughout the activation
of prothrombin by prothrombinase assembled with factor
Va
Δ659-663 or factor Va
5K. The excess meizothrombin present
intheassays,while havingpoorclottingactivity,cancompensate
for the lack of thrombin activity because of its increased
amidolytic activity toward chromogenic substrates (49, 50)t h a t
are usually employed to assess thrombin activity, thus creating
the false impression that the mutations have a minimal effect on
prothrombinase activity. As a consequence, and because factor
Va is devoid of enzymatic activity, when recombinant mutant
factor Va molecules are being studied, drawing conclusions from
activity assays only, without visualizing the pathwaytothrombin
generation,wouldleadtoincorrectinterpretationswithregardto
the functional contribution of a given amino acid sequence from
factor Va on the rates of the specific prothrombin activating
cleavages. We therefore conclude that following the activity of
various recombinant mutant factor Va molecules by clotting
FIGURE 12: Analysis of FPR-meizothrombin consumption by pro-
thrombinase assembled with recombinant factor Va molecules. The
gels shown in Figure 11 were scanned, and FPR-meizothrombin
consumptionwasrecordedasdescribedinExperimentalProcedures.
Following scanning densitometry, the data representing fragment
132-Aconsumptionasafunctionoftime(seconds)wereplottedusing
nonlinear regression analysis according to the equation representing
a first-order exponential decay using Prism (GraphPad) asdescribed
in the legend of Figure 6. The apparent first-order rate constant, k
(inverse seconds), was obtained directly from the fitted data. Pro-
thrombinase was assembled with recombinant factor Va
WT [(2) R
2=
0.99], factor Va
Δ659-663 [(9) R
2 = 0.99], factor Va
5K [(0) R
2 = 0.98],
and factor Va
5A [(3) R
2 = 0.99]. The resulting numbers representing
FPR-meizothrombin consumption are reported in Table 3.Article Biochemistry, Vol. 49, No. 39, 2010 8533
assays, gel electrophoresis analyses, and assays using chromo-
genic substrates is by no means redundant and prevents over-
simplification that in turn might lead to flawed conclusions.
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